前列腺癌根治术后早期生化复发:18F-fluciclovine与PSMA PET-CT头对头比较
这项前瞻性、单中心、单臂比较研究在50例根治术后生化复发且PSA 0·2–2·0 ng/mL的患者中配对比较18F-fluciclovine与PSMA PET-CT。PSMA在患者水平、盆腔淋巴结及盆腔外病灶的检出率均显著更高,提示低PSA复发定位时PSMA应作为首选示踪剂。
要点
- PSA≤2·0 ng/mL生化复发时,PSMA PET-CT患者水平检出率56%,高于18F-fluciclovine的26%。
- 盆腔淋巴结区检出率PSMA为30%,18F-fluciclovine为8%,差异显著。
- 检出率提高是否转化为肿瘤学获益尚需进一步研究。
核心结论
- 在前列腺癌根治术后生化复发且PSA≤2·0 ng/mL的患者中,PSMA PET-CT检出率显著高于18F-fluciclovine PET-CT,PSMA应作为PET-CT示踪剂首选。
研究设计与样本
- 前瞻性、单中心、开放标签、单臂比较研究,于美国加州大学洛杉矶分校开展。
- 纳入根治术后生化复发、PSA 0·2–2·0 ng/mL、未接受挽救治疗且Karnofsky评分≥50的>18岁患者。
- 50例患者均在15天内完成18F-fluciclovine(参考试验)与PSMA(索引试验)PET-CT,每份图像由3名独立设盲读者判读并以2比1多数共识确定阳性。
- 功效分析提示需50例方能显示PSMA检出率优效22%的差异;中位随访8个月(IQR 7–9)。
主要发现
- 患者水平检出率:18F-fluciclovine 13/50(26%;95%CI 15–40),PSMA 28/50(56%;41–70),OR 4·8(95%CI 1·6–19·2;p=0·0026)。
- 盆腔淋巴结区检出率:18F-fluciclovine 4/50(8%;2–19),PSMA 15/50(30%;18–45),OR 12·0(95%CI 1·8–513·0;p=0·0034)。
- 盆腔外病灶检出率:18F-fluciclovine 0/50(0%;0–6),PSMA 8/50(16%;7–29),OR不可估计(95%CI不可估计;p=0·0078)。
关键数值与推荐
- 主要终点为患者水平及按解剖区域的生化复发检出率,研究达到主要终点。
- NCCN指南考虑18F-fluciclovine PET-CT用于根治术后生化复发定位,EAU指南推荐PSMA PET-CT。
- 本研究为上述两种示踪剂的首个头对头前瞻性比较。
临床怎么用
- 根治术后低PSA(≤2·0 ng/mL)生化复发、拟以PET-CT指导后续治疗决策时,应优先选择PSMA PET-CT。
- 18F-fluciclovine在盆腔外病灶检出上极为有限,可能影响分期与挽救治疗规划。
局限性
- 单中心、单臂设计,样本量50例,随访仅8个月。
- 未评估检出率提高是否转化为肿瘤学结局改善。
- 研究无资助,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: National Comprehensive Cancer Network guidelines consider 18F-fluciclovine PET-CT for prostate cancer biochemical recurrence localisation after radical prostatectomy, whereas European Association of Urology guidelines recommend prostate-specific membrane antigen (PSMA) PET-CT. To the best of our knowledge, no prospective head-to-head comparison between these tests has been done so far. The aim of this study was to compare prospectively paired 18F-fluciclovine and PSMA PET-CT scans for localising biochemical recurrence of prostate cancer after radical prostatectomy in patients with low prostate-specific antigen (PSA) concentrations (<2·0 ng/mL). METHODS: This was a prospective, single-centre, open-label, single-arm comparative study done at University of California Los Angeles (Los Angeles, CA, USA). Patients older than 18 years of age with prostate cancer biochemical recurrence after radical prostatectomy and PSA levels ranging from 0·2 to 2·0 ng/mL without any prior salvage therapy and with a Karnofsky performance status of at least 50 were eligible. Patients underwent 18F-fluciclovine (reference test) and PSMA (index test) PET-CT scans within 15 days. Detection rate of biochemical recurrence at the patient level and by anatomical region was the primary endpoint. A statistical power analysis demonstrated that a sample size of 50 patients was needed to show a 22% difference in detection rates in favour of PSMA (test for superiority). Each PET scan was interpreted by three independent masked readers and a consensus majority interpretation was generated (two vs one) to determine positive findings. This study is registered with ClinicalTrials.gov, number NCT02940262, and is complete. FINDINGS: Between Feb 26, 2018, and Sept 20, 2018, 143 patients were screened for eligibility, of whom 50 patients were enrolled into the study. Median follow-up was 8 months (IQR 7-9). The primary endpoint was met; detection rates were significantly lower with 18F-fluciclovine PET-CT (13 [26%; 95% CI 15-40] of 50) than with PSMA PET-CT (28 [56%; 41-70] of 50), with an odds ratio (OR) of 4·8 (95% CI 1·6-19·2; p=0·0026) at the patient level; in the subanalysis of the pelvic nodes region (four [8%; 2-19] with 18F-fluciclovine vs 15 [30%; 18-45] with PSMA PET-CT; OR 12·0 [1·8-513·0], p=0·0034); and in the subanalysis of any extrapelvic lesions (none [0%; 0-6] vs eight [16%; 7-29]; OR non-estimable [95% CI non-estimable], p=0·0078). INTERPRETATION: With higher detection rates, PSMA should be the PET tracer of choice when PET-CT imaging is considered for subsequent treatment management decisions in patients with prostate cancer and biochemical recurrence after radical prostatectomy and low PSA concentrations (≤2·0 ng/mL). Further research is needed to investigate whether higher detection rates translate into improved oncological outcomes. FUNDING: None.
引用
- Calais J, Ceci F, Eiber M, et al. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019. PMID: 31375469. doi:10.1016/S1470-2045(19)30415-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。